Citations

Showing 10 of 108104 citations.

Liraglutide and Weight Loss Among Patients with Advanced Heart Failure and a Reduced Ejection Fraction: Insights from the FIGHT Trial
Sharma, Abhinav , Ambrosy, Andrew P. , McNulty, Steven E., Mentz, Robert J. , Cooper, Lauren B. , Lala, Anuradha , Groake, John D., Borlaug, Barry A. , Borlaug, Barry A , Mentz, Robert J , DeVore, Adam D. , Margulies, Kenneth B. , Hernandez, Adrian F. , Felker, G. Michael , Vader, Justin M. , Velazquez, Eric J.

Mayo Clinic

ESC Heart Failure | August 18, 2018 | Volume: 5 | Issue: 6 | Pages: 1035-1043

10.1002/ehf2.12334 | PMID 30120812 Get It

Abstract Aims Obesity is present in up to 45% of patients with heart failure (HF). Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor antagonist, facilitates weight loss in obese patients. The efficacy of liraglutide as a weight loss agent among patients with HF and reduced ejection fraction (HFrEF) and a recent acute HF hospitalization remains unknown. Methods and results The Functional Impact of GLP-1 for Heart Failure Treatment study randomized 300 patients with HFrEF (ejection fraction ≤ 40%), both with and without diabetes and a recent HF hospitalization to liraglutide or placebo. The primary outcome for this post hoc analysis was the change in weight from baseline to last study visit. We conducted an ‘on-treatment’ analysis of patients with at least one follow-up visit on study drug (123 on liraglutide and 124 on placebo). The median age was 61 years, 21% were female, and 69% of patients had New York Heart Association functional Class III or IV symptoms. The median ejection fraction was 25% (25th, 75th percentile 19–32%). Liraglutide use was associated with a significant weight reduction [liraglutide −1.00 lbs vs. placebo 2.00 lbs; treatment difference −4.10 lbs; 95% confidence interval (CI) −7.94, −0.25; P = 0.0367; percentage treatment difference −2.07%, 95% CI −3.86, −0.28; P = 0.0237]. Similar results were seen after multivariable adjustments. Liraglutide also significantly reduced triglyceride levels (liraglutide 7.5 mg/dL vs. placebo 12.0 mg/dL; treatment difference −33.1 mg/dL; 95% CI −60.7, −5.6; P = 0.019). Conclusions Liraglutide is an efficacious weight loss agent in patients with HFrEF. These findings will require further exploration in a well-powered cardiovascular outcomes trial.
Emergency Department Visits After Elective Spine Surgery
Hills, Jeffrey M. , Khan, Inamullah , Sivaganesan, Ahilan, Weisenthal, Benjamin M., Daryoush, Joshua R. , Butler, Marjorie, Bydon, Mohamad , Archer, Kristin R. , Asher, Anthony L. , Devin, Clinton J.

Mayo Clinic

Neurosurgery | August 17, 2018 | Volume: 85 | Issue: 2 | Pages: E258-E265

10.1093/neuros/nyy445 | PMID 30272232 Get It

Abstract BACKGROUND Emergency department (ED) overuse is a costly and often neglected source of postdischarge resource utilization after spine surgery. Failing to investigate drivers of ED visits represents a missed opportunity to improve the value of care in spine patients. OBJECTIVE To identify the prevalence, drivers, and timing of ED visits following elective spine surgery. METHODS Patients undergoing elective spine surgery for degenerative disease at a major medical center were enrolled in a prospective longitudinal registry. Patient and surgery characteristics, and patient-reported outcomes were recorded at baseline and 3 mo after surgery, along with self-reported 90-d ED visits. A multivariable regression model was used to identify independent factors associated with 90-d ED visits. For a sample of patients presenting to our institution's ED, charts were reviewed to identify the reason and time to ED postdischarge. RESULTS Of 2762 patients, we found a 90-d ED visit rate of 9.4%. One-third of patients presented to our institution's ED and of these, 70% presented due to pain or medical concerns at 9 and 7 d postdischarge, respectively, with 60% presenting outside normal clinic hours. Independent risk factors for 90-d ED visits included younger age, preoperative opioid use, chronic obstructive pulmonary disorder, and more vertebral levels involved. CONCLUSION Nearly 10% of elective spine patients had 90-d ED visits not requiring readmission. Pain and medical concerns accounted for 70% of visits at our center, occurring within 10 d of discharge. This study provides the clinical details and a timeline necessary to guide individualized interventions to prevent unnecessary, costly ED visits after spine surgery.
Pearce Bailey: The “Fifth Horseman” and the National Institute for Neurological Diseases and Blindness
Burkholder, David B. , Burkholder, David B

Mayo Clinic

Journal of the History of the Neurosciences | August 17, 2018 | Volume: 27 | Issue: 3 | Pages: 303-309

10.1080/0964704x.2018.1486675 | PMID 30118410 Get It

Adolph Sahs: A neurologist who could take on still another job
Boes, Christopher J.

Mayo Clinic

Journal of the History of the Neurosciences | August 17, 2018 | Volume: 27 | Issue: 3 | Pages: 251-257

10.1080/0964704x.2018.1486669 | PMID 30118416 Get It

Abstract LB-343: Development of plasma cell-free DNA (cfDNA) assays for early cancer detection: first insights from the Circulating Cell-Free Genome Atlas Study (CCGA)
Aravanis, Alexander A., Oxnard, Geoffrey R. , Maddala, Tara, Venn, Oliver, Jamshidi, Arash , Shen, Ling , Amini, Hamed , Beausang, John F., Betts, Craig, Civello, Daniel, Davydov, Konstantin , Fazullina, Saniya, Filippova, Darya , Gnerre, Sante, Gross, Samuel, Hou, Chenlu, Jiang, Roger, Jung, Byoungsok , Melton, Collin, Nautiyal, Shivani , Newman, Joshua, Nicolaou, Cosmos , Rava, Richard P., Sakarya, Onur, Satya, Ravi Vijaya, Shojaee, Seyedmehdi, Steffen, Kristan K., Valouev, Anton, Xu, Hui , Yue, Jeanne, Baselga, José, Lapham, Rosanna L., Davis, Daron G., Richards, Donald, Seiden, Michael V., Yeatman, Timothy J. , Tibshirani, Robert , Curtis, Christina , Plevritis, Sylvia K. , Williams, Richard T. , Hartman, Anne‐Renee , Liu, Minetta C. , Aravanis, Alexander M. , Hubbell, Earl , Davydov, Konstantin, Gross, Samuel, Jiang, Roger, Kurtzman, Kathryn N. , Newman, Jonathan D , Newman, Joshua, Zhang, Nan , Smith, David A. B. , Swanton, Charles , Klein, Eric A.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: LB-343-LB-343

10.1158/1538-7445.am2018-lb-343 Get It

Abstract CCGA [NCT02889978] is the largest study of cfDNA-based early cancer detection; the first CCGA learnings from multiple cfDNA assays are reported here. This prospective, multi-center, observational study has enrolled 10,012 of 15,000 demographically-balanced participants at 141 sites. Blood was collected from participants with newly diagnosed therapy-naive cancer (C, case) and participants without a diagnosis of cancer (noncancer [NC], control) as defined at enrollment. This preplanned substudy included 878 cases, 580 controls, and 169 assay controls (n=1627) across 20 tumor types and all clinical stages. All samples were analyzed by: 1) Paired cfDNA and white blood cell (WBC)-targeted sequencing (60,000X, 507 gene panel); a joint caller removed WBC-derived somatic variants and residual technical noise; 2) Paired cfDNA and WBC whole-genome sequencing (WGS; 35X); a novel machine learning algorithm generated cancer-related signal scores; joint analysis identified shared events; and 3) cfDNA whole-genome bisulfite sequencing (WGBS; 34X); normalized scores were generated using abnormally methylated fragments. In the targeted assay, non-tumor WBC-matched cfDNA somatic variants (SNVs/indels) accounted for 76% of all variants in NC and 65% in C. Consistent with somatic mosaicism (i.e., clonal hematopoiesis), WBC-matched variants increased with age; several were non-canonical loss-of-function mutations not previously reported. After WBC variant removal, canonical driver somatic variants were highly specific to C (e.g., in EGFR and PIK3CA, 0 NC had variants vs 11 and 30, respectively, of C). Similarly, of 8 NC with somatic copy number alterations (SCNAs) detected with WGS, 4 were derived from WBCs. WGBS data revealed informative hyper- and hypo-fragment level CpGs (1:2 ratio); a subset was used to calculate methylation scores. A consistent “cancer-like” signal was observed in <1% of NC participants across all assays (representing potential undiagnosed cancers). An increasing trend was observed in NC vs stages I-III vs stage IV (nonsyn. SNVs/indels per Mb [Mean±SD] NC: 1.01±0.86, stages I-III: 2.43±3.98; stage IV: 6.45±6.79; WGS score NC: 0.00±0.08, I-III: 0.27±0.98; IV: 1.95± 2.33; methylation score NC: 0±0.50; I-III: 1.02±1.77; IV: 3.94±1.70). These data demonstrate the feasibility of achieving >99% specificity for invasive cancer, and support the promise of cfDNA assay for early cancer detection. Additional data will be presented on detected plasma:tissue variant concordance and on multi-assay modeling. Citation Format: Alexander A. Aravanis, Geoffrey R. Oxnard, Tara Maddala, Earl Hubbell, Oliver Venn, Arash Jamshidi, Ling Shen, Hamed Amini, John A. Beausang, Craig Betts, Daniel Civello, Konstantin Davydov, Saniya Fazullina, Darya Filippova, Sante Gnerre, Samuel Gross, Chenlu Hou, Roger Jiang, Byoungsok Jung, Kathryn Kurtzman, Collin Melton, Shivani Nautiyal, Jonathan Newman, Joshua Newman, Cosmos Nicolaou, Richard Rava, Onur Sakarya, Ravi Vijaya Satya, Seyedmehdi Shojaee, Kristan Steffen, Anton Valouev, Hui Xu, Jeanne Yue, Nan Zhang, Jose Baselga, Rosanna Lapham, Daron G. Davis, David Smith, Donald Richards, Michael V. Seiden, Charles Swanton, Timothy J. Yeatman, Robert Tibshirani, Christina Curtis, Sylvia K. Plevritis, Richard Williams, Eric Klein, Anne-Renee Hartman, Minetta C. Liu. Development of plasma cell-free DNA (cfDNA) assays for early cancer detection: first insights from the Circulating Cell-Free Genome Atlas Study (CCGA) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-343.
Abstract LB-305: Randomized, double-blind, placebo-controlled immunoprevention trial with MUC1 vaccine in patients with newly diagnosed advanced adenomas
Boardman, Lisa A., Bansal, Ajay , Beatty, Pamela , Hur, Chin , Dzubinski, Lynda , Rodriguez, Luz M. , Salazar, Andres , McKolanis, John , Seisler, Drew K., Foster, Nathan R. , Polley, May-Yin, Finn, Olivera J. , Schoen, Robert E. , Boardman, Lisa A., Cruz‐Correa, Marcia , Kastenberg, David , RODRIGUEZ, LUZ MARIA , Limburg, Paul J.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: LB-305-LB-305

10.1158/1538-7445.am2018-lb-305 Get It

Abstract Background: Immunotherapy targeting tumor-associated antigens aberrantly expressed on colorectal cancers and adenomatous polyps offers the potential for a relatively non-invasive and non-toxic prevention strategy, and because of the specificity of the immune response and its long-term memory, the potential for prolonged protection. In a double-blind randomized trial in patients with a diagnosis of advanced colorectal adenomas within the previous year, we are evaluating MUC1 vaccine with the TLR-3 agonist polyICLC (Hiltonol®) as an adjuvant, for its immunogenicity and effect on colorectal adenoma recurrence at follow up colonoscopy. Aim: We report on a primary endpoint, MUC1 immunogenicity at week 12 (following vaccine or placebo administration at 0, 2, and 10 weeks), and on determinants of the immune response and vaccine toxicity. Methods: Subjects with an advanced adenoma (defined as ≥1cm, tubulovillous or villous histology, or with HGD) were randomized. Response to the vaccine was assessed by monitoring IgG anti-MUC1 antibody titer ratio; defined as t12/t0, where t0 is the initial titer measured prior to vaccination, and t12 is the titer drawn at 12 weeks. A ratio of 2.0 was used as the primary definition of a significant immune response. T Regulatory and myleoid derived suppressor cell (MDSC) levels at baseline were assessed in relation to vaccine response. Adverse events (AEs) were recorded according to NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Results: 102 subjects were randomized at 6 centers, 52 received MUC1 vaccine and 50 placebo. Subjects had a mean age of 59.4±7.0 (range 40-70) years, 60.8% were male, 88.2% were white, and 18.6% Hispanic or Latino. At 12 weeks the IgG ratio was ≥2.0 in 13/52 (25%) of patients receiving vaccine (ratio range 2.9-17.3), vs. 0/50 in placebo group (P=.0001), and was ≥1.5 in 19/52 (36.5%) of patients receiving vaccine compared to 1/50 (2%) in placebo group (P<.0001). In the vaccinated group, the IgG ratio was ≥2.0 in 45% of women (9/20) vs. 12.5% of men (4/32) (P=0.009) and ≥1.5 in 55% of women (11/20) vs. 25% of men (8/32) (P=0.03). In the vaccinated group, reduced levels of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) pre-vaccination were associated with response, 0.2±0.1 among responders (n=13) vs. 0.8±1.1 among non-responders (N=39) (p=0.0006) whereas monocytic MDSC and T regulatory cells (CD4+CD25, Foxp3) were not. There were no grade 3 adverse events (AE) possibly or probably related to the vaccine. The most common AE was an injection site reaction (grade 1 or 2) which occurred in 80.8% (n=42/52) in vaccine group vs. 6.0% in the placebo group (3/50). Conclusions: Subjects with an advanced adenoma receiving MUC1 vaccine compared with a placebo are significantly more likely to develop an anti-IgG MUC1 immune response at 12 weeks. Women and subjects with lower circulating PMN-MDSC levels at baseline were more likely to respond. The vaccine was well tolerated. Follow up for the effect of the vaccine on adenomatous polyp recurrence is ongoing. Citation Format: Robert E. Schoen, Lisa A. Boardman, Marcia Cruz-Correa, Ajay Bansal, Pamela L. Beatty, David Kastenberg, Chin Hur, Lynda Dzubinski, Luz Rodriguez, Andres Salazar, John McKolanis, Drew Seisler, Nathan R. Foster, May-Yin Polley, Paul J. Limburg, Olivera J. Finn. Randomized, double-blind, placebo-controlled immunoprevention trial with MUC1 vaccine in patients with newly diagnosed advanced adenomas [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-305.
Abstract LB-281: β-catenin signaling mediates pathogenic pro-inflammatory conversion of Foxp3+ Treg cells early during colon cancer development
Quandt, Jasmin , Haghi, Leila, Emmanuel, Akinola Olumide , Khazaie, Khashayarsha , Gounari, Fotini

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: LB-281-LB-281

10.1158/1538-7445.am2018-lb-281 Get It

Abstract In the present study we provide a temporal and mechanistic explanation of how β-catenin signaling skews regulatory T cells (Treg) into a pathogenic, pro-inflammatory phenotype that co-express the Th17 lineage transcription factor RORγt along with Foxp3 during colon cancer (CC) development. We previously described this distinct subset of Tregs in the peripheral blood (PB) of established CC patients that suppresses effector T cell functions but simultaneously maintains inflammation by failing to regulate mast cell degranulation and production of IL-17. Moreover, we showed in mice that RORγt expression correlates with elevated β-catenin levels in T cells and that RORγt is a transcriptional target of β-catenin interaction partners TCF-1 (Tcf7) and HEB (Tcf12). To elucidate how Wnt/β-catenin signaling orchestrates the induction of pathogenic properties in Tregs specifically we analyzed inflammatory bowel disease (IBD) patients' tissue and PB. As IBD can progress to colon cancer, this disease presents a unique platform to study the temporal emergence of RORγt+/Foxp3+ Tregs during the course of the disease. To further mechanistically establish how activated β-catenin signaling facilitates re-programming of Tregs and acquisition of pro-inflammatory properties we over-expressed β-catenin specifically in Tregs and/or knocked out its interaction partners TCF-1 and HEB in a Foxp3-Cre mouse model. Indeed, in a specific sub-population of IBD patients we were able to detect RORγt+/Foxp3+ double positive Tregs in the patients' blood and tissue, expressing high levels of β-catenin and producing IL-17 upon re-stimulation. Mice expressing β-catenin Treg-specifically showed striking X-linked immune pathology. Males died 4 weeks after birth of a severe scurfy-like phenotype, indicating failure of Treg function. β-catenin overexpressing Tregs in mice displayed a reduced suppressive capacity, higher rate of apoptosis and produced effector cytokines IL-17 and IFN-γ. Furthermore, the chromatin accessibility of bona fide Treg genes was drastically reduced, whereas accessibility in T cell activation and IL-17 signature genes increased compared to wild-type Tregs in ATACseq analysis. An additional Treg-specific knock-out of HEB or TCF-1 reduced or delayed auto-immunity, respectively, with increased survival in both cases and partial rescue of systemic Treg numbers. We herewith provide evidence that induction of β-catenin signaling is indeed responsible for the pathogenic, pro-inflammatory conversion of Tregs through activation of RORγt expression. Further transcriptome analysis will reveal how the epigenetic changes in the chromatin translate to gene expression. We anticipate, that this mechanistic insight into β-catenin mediated pathogenic conversion of Tregs will reveal novel targets for cancer immuno-therapy. Citation Format: Jasmin Quandt, Leila Haghi, Akinola O. Emmanuel, Khashayarsha Khazaie, Fotini Gounari. β-catenin signaling mediates pathogenic pro-inflammatory conversion of Foxp3+ Treg cells early during colon cancer development [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-281.
Abstract LB-250: Oncogenic activation of mitochondrial phosphocreatine energy shuttle creates a druggable metabolic liability in cancer cells
Hitosugi, Taro , Kurmi, Kiran

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: LB-250-LB-250

10.1158/1538-7445.am2018-lb-250 Get It

Abstract Many important metabolic processes such as energy homeostasis, regulation of reactive oxygen species (ROS) levels, production of signaling metabolites, and synthesis of precursors for macromolecules occur in mitochondria of cancer cells. However, targeting mitochondrial metabolism in cancer has been challenging due to toxicity in normal cells, which also depend on mitochondrial metabolism. Therefore, identification of tumor specific mitochondrial metabolic alterations would be crucial to develop drugs that can selectively target cancer cells while sparing normal tissue. Here, by using targeted metabolite profiling and mitochondria-specific phospho-proteomics approach, we identified Mitochondrial Creatine Kinase (MtCK) 1 as a metabolic target in HER2+ breast cancer cells. We show that the oncogenic HER2-ABL axis stabilizes MtCK1 through tyrosine 153 (Y153) phosphorylation to activate the PCr energy shuttle pathway that transfers ATP from mitochondria to cytosol. Inhibition of the PCr energy shuttle pathway either by genetically depleting MtCK1 or by pharmacologically with a creatine analogue cyclocreatine, decreases proliferation of trastuzumab-sensitive and -resistant HER2+ cancer cells and reduces tumor growth in vivo without obvious toxicity. These findings suggest that, once ATP is produced in the mitochondria, it is equally important for breast cancer cells to transfer this energy from mitochondria to the cytosol for maintenance of various biochemical processes and tumor growth. In summary, our study reveals MtCK1 stabilization by Y153 phosphorylation as a key molecular mechanism underlying the intersection between oncogenic HER2 signaling and mitochondrial energy metabolism, which creates a druggable metabolic vulnerability in cancer. Since cyclocreatine has been used as a dietary sport supplement, cyclocreatine might be able to inhibit trastuzumab-resistant tumors with much less toxicity in patients as compared to conventional anticancer drugs. Citation Format: Taro Hitosugi, Kiran Kurmi. Oncogenic activation of mitochondrial phosphocreatine energy shuttle creates a druggable metabolic liability in cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-250.
Abstract LB-235: DNA methylation of individual repetitive elements in HCV infection-induced HCC
Ren, Jimmy, Hlady, Ryan A. , Murphy, Robert L. , Roberts, Lewis R. , Hou, Lifang , Roberts, Lewis R , Murphy, Robert , Hou, Lifang , Zheng, Yinan , Robertson, Keith D.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: LB-235-LB-235

10.1158/1538-7445.am2018-lb-235 Get It

Abstract Hepatocellular carcinoma (HCC) is the second most common cause of cancer deaths worldwide. Hepatitis C virus (HCV) infection is a major risk factor for HCC in the US. HCV infection may cause cancer by suppressing host defense that controls the propagation of repetitive element (RE) sequences, including LINE-1 and Alu, the most representative REs in the human genome. DNA methylation of RE helps stabilize the genome, while reduced RE methylation, also referred as global hypomethylation, leads to genomic instability and is known as a hallmark of cancer. However, current available high-throughput technology for DNA methylation profiling only enables genomewide RE methylation study on a global scale. The role of individual RE methylation in cancer is largely understudied. In this study, using our recently developed and published machine learning algorithm to enhance the RE coverage of the Illumina methylation array platform, we examined the role of individual RE methylation in HCV-induced HCC across the entire genome. We conducted an epigenome-wide association study on 22 HCC, 20 cirrhotic, and 44 normal liver tissues. We included equal numbers of HCV-induced and alcohol-induced HCC/cirrhosis cases. The Illumina 450k array profiled 1939 REs and we computationally predicted 33184 REs; correlations between the overlapping 1541 profiled and predicted RE methylation were > 0.91. Sex, tumor differentiation, and tumor stage were similarly distributed across the HCV and alcohol groups. We adjusted for batch effects and used Benjamini-Hochberg adjusted false discovery rate (FDR) to account for multiple testing. Relative to normal liver tissue, we observed over twice as many differentially methylated (FDR < 0.05) REs in HCV-HCC compared to alcohol-HCC tissue (2911 vs 1304, 749 in common). We validated our results in The Cancer Genome Atlas (TCGA) (325 vs 129, 74 in common) with high correlation (r = 0.90). We also observed that 169 REs were significantly altered in HCV-cirrhosis tissue (compared to none in alcohol-cirrhosis tissue), of which, 17 REs in 13 genes, including PIK3CD, LY9, GCK, NLRC3, and PRKCZ, were consistently hypomethylated in both HCC and cirrhotic liver tissue induced by HCV (r = 0.87). Using TCGA RNA sequencing data, we found that these REs were located in gene body and their hypomethylation was associated with lower expression of their host genes (r > 0.3, p < 0.05). Gene Ontology Enrichment analysis showed that these genes were enriched in T-cell activation & differentiation and cytokine production (FDR < 0.05). Our findings indicate that HCV infection has a more extensive impact on the DNA methylation landscape in RE than alcohol consumption, and that HCV infection may also induce similar hypomethylation in cirrhotic liver. Hypomethylated RE may alter local chromatin environment and disrupt expression of genes involved in immune and inflammatory responses, both of which may promote HCC development. RE hypomethylation in specific genomic locus may serve as early detection biomarker of HCC in patients with HCV-induced cirrhosis. Citation Format: Yinan Zheng, Jimmy Ren, Ryan A. Hlady, Keith D. Robertson, Robert L. Murphy, Lewis R. Roberts, Lifang Hou. DNA methylation of individual repetitive elements in HCV infection-induced HCC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-235.
Abstract LB-196: EGFR-mutant lung adenocarcinomas mutation profiles reveal ARID1A might be a novel tyrosine kinase resistance pathway
Gao, Xuyuan , Xu, Hang , Ho, Jcm , Chan, Oscar SH, Xu, Feng , Wang, Junwen , Lee, Victor , Tin, Vicky Pc, Xiao, Zhijie , Yam, Judy Wai Ping , Wong, Maria Pik , Wang, Junwen , Gao, Xuyuan, Wang, Siqi

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: LB-196-LB-196

10.1158/1538-7445.am2018-lb-196 Get It

Abstract Lung cancer has the highest mortality across all cancers in the world. Epidermal growth factor receptor (EGFR) is commonly mutated in lung adenocarcinomas from Asian non-smoking females. These tumors usually respond to EGFR tyrosine kinase inhibitors (EGFR-TKI), but the outcomes vary in different patients. Though EGFR T790M, amplification of MET and other mechanisms have been shown to confer EGFR-TKI resistance, the molecular mechanisms in around 30% of patients are still unknown. To uncover novel candidate pathways of EGFR-TKI resistance, we analyzed the whole exome mutation profiles of pre-treatment, EGFR T790M-free lung adenocarcinomas with typical activating mutations (L858R, exon 19 deletions). Amongst 19 non-responding (NR) tumors without significant shrinkage after gefitinib or erlotinib treatment, 67 cancer-related genes showed coding region non-synonymous single nucleotide variations (SNV) or insertion-deletions (indels) but they were not detected in 22 responding tumors. Gene set enrichment analysis (GSEA) showed 14 of the 67 genes were involved in the EGFR and WNT signaling network (false discovery rate q=1.14 e-8 for EGFR and q=4.3 e-9 for WNT), including well-known TKI resistance-related genes PIK3CA, PTEN and NF1. Notably, ARID1A, which encodes a subunit of the chromatin remodeling complex, showed nonsense mutations in 2 NR but not responding tumors, which were validated by Sanger sequencing. More than 40% of ARID1A mutations in lung adenocarcinomas recorded in COSMIC were nonsense mutations or frameshift indels. Loss of function mutations of ARID1A have also been reported in various cancers, together suggesting ARID1A might be a tumor suppressor but its involvement in EGFR mutant lung cancers is unknown. To investigate the potential role of ARID1A, its expression was first studied using Kaplan-Meier plotter. Low expression of ARID1A is associated with significantly better overall survival than high expression level in lung adenocarcinoma patients (p=8.5 e-7). To test whether loss of ARID1A could cause TKI resistance, ARID1A was knocked down by shRNA in HCC827 lung cancer cell line harboring EGFR exon19 deletion. MTT cell viability assay using gefitinib showed increase of IC50. Western blot assay further showed ARID1A knockdown increased phosphorylation of AKT at Ser473. Together, the findings suggest loss of ARID1A could lead to EGFR bypass and promote activation of the downstream PI3K/AKT pathway, leading to EGFR TKI resistance. Overall, our findings suggest EGFR-TKI resistance mutations could be detected before TKI drug selection. Resistant gene mutations present in pre-treatment tumors could help to predict the treatment response. More specifically, our study identified a promising gene list involved in EGFR-TKI resistance, and suggested ARID1A loss could be a novel EGFR-TKI resistance mechanism. Citation Format: Xuyuan Gao, Hang Xu, James CM Ho, Oscar SH Chan, Feng Xu, Junwen Wang, Victor HF Lee, Vicky PC Tin, Zhijie Xiao, Siqi Wang, Judy WP Yam, Maria P Wong. EGFR-mutant lung adenocarcinomas mutation profiles reveal ARID1A might be a novel tyrosine kinase resistance pathway [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-196.